Adjei, Alex A.

Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical care journals

Lederer, D. J., Bell, S. C., Branson, R. D., Chalmers, J. D., Marshall, R., Maslove, D. M., Ost, D. E., Punjabi, N. M., Schatz, M., Smyth, A. R., et al. (2019) · Annals of the American Thoracic Society

Advanced Causal Inference TechniquesStatistical Methods in Epidemiology

Cited by 715

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 645

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians

Chemotherapy-related skin toxicityLung Cancer Treatments and Mutations

Cited by 331

Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals

Leisman, D. E., Harhay, M. O., Lederer, D. J., Abramson, M., Adjei, A. A., Bakker, J., Ballas, Z. K., Barreiro, E., Bell, S. C., Bellomo, R., et al. (2020) · Critical Care Medicine

Statistical Methods in EpidemiologyMeta-analysis and systematic reviews

Cited by 271

KRAS: From undruggable to a druggable Cancer Target

Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 271

Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer

Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 219

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 155

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

Friday, B. B., Yu, C., Dy, G. K., Smith, P. D., Wang, L., Thibodeau, S. N., & Adjei, A. A. (2008) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 146

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 93

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

Adjei, A. A., Schwartz, B., & Garmey, E. (2011) · The Oncologist

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 73

Signal transduction pathway targets for anticancer drug discovery

Adjei, A. (2000) · Current Pharmaceutical Design

Protein Kinase Regulation and GTPase SignalingCancer Mechanisms and Therapy

Cited by 33

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

Ma, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., Goff, L. W., Alberts, S., Bui, L. A., Sanghal, A., et al. (2021) · Cancer Chemotherapy and Pharmacology

Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

Cited by 12

Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors.

Lieu, C. H., Beeram, M., Harb, W. A., Kearns, J. D., Sloss, C. M., Nering, R., Adjei, A. A., & Wolf, B. B. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesMonoclonal and Polyclonal Antibodies Research

Cited by 7

Abstract 3870: The addition of CB-839 to temozolomide significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model

Kizilbash, S. H., Burgenske, D. M., McBrayer, S., Devarajan, S., Gupta, S. K., Hitosugi, T., He, L., Schroeder, M. A., Carlson, B. L., Gelman, M., et al. (2019) · Cancer Research

Glioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

Cited by 4

Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data.

Ashruf, O., Mushtaq, A., Lin, C. (.-T., Volk, M., Orozco, Z., Hundal, J., Safdar, A., Thompson, C., Karimi, S., Jain, A. G., et al. (2025) · Journal of Clinical Oncology

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 4